Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-11-18 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing the discovery of a new class of antimalarial compounds, describing research findings, and providing background on the company's malaria initiatives. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is primarily a regulatory announcement of new scientific research and corporate social responsibility efforts, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement and press release that does not fit other specific categories.
2011-11-18 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG to the SEC regarding their Form 20-F for the fiscal year ended December 31, 2010, filed on January 27, 2011. The letter addresses SEC staff comments from a conference call and proposes revised disclosure text related to patent life and exclusivity periods for pharmaceutical compounds. It is a correspondence responding to regulatory comments rather than the actual Form 20-F report or a financial statement. The document contains no financial data or comprehensive report content but is a regulatory correspondence related to a previously filed annual report. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory communication and not the report itself.
2011-11-14 English
6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the appointment of a new Global Head of Development at Novartis Pharmaceuticals. There are no financial statements, detailed financial data, or comprehensive management discussion. The document is an announcement of a management appointment, which fits the category of Board/Management Information (MANG). The document length is 6365 characters, which is sufficient to contain substantive information, and the content is clearly about a management change rather than a financial report or other filing type.
2011-11-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing Phase III clinical trial results for a drug (ACZ885) related to systemic juvenile idiopathic arthritis (SJIA). It includes detailed study results, safety data, and plans for regulatory submissions. The document is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing that provides material information to investors but does not fit into other specific categories such as earnings release, annual report, or management report. It is a typical use of Form 6-K to disclose material news by foreign issuers. Therefore, the appropriate classification is Regulatory Filings (RNS).
2011-11-07 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing Phase II clinical trial data for a drug candidate (DEB025) for hepatitis C. It includes detailed clinical results, study descriptions, and forward-looking statements. There are no financial statements or comprehensive financial data typical of annual or interim reports. The document is not a transcript, audit report, or management change announcement. It is a regulatory filing used to disclose material information to investors outside of the annual or quarterly report cycle. Given the nature of the document as a Form 6-K with a press release, it fits best under Regulatory Filings (RNS).
2011-11-07 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes detailed financial performance data for the third quarter and nine months of 2011, including net sales, operating income, net income, EPS, and free cash flow. It also discusses pipeline progress, product approvals, and restructuring plans. The document contains comprehensive financial figures and analysis for a period shorter than a full fiscal year (quarterly and nine months), which aligns with the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, contains substantive financial data and analysis, and is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2011-10-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.